Definiens and Cenix BioScience Enter into Licensing and Co-Marketing Agreement in High-Content Screening
Definiens and Cenix BioScience announced that they have entered into a licensing and co-marketing agreement. This step represents the formalization of an ongoing and strong relationship, as the two companies have been working together for several years now. The two companies' offerings are ideally complementary and the agreement will therefore build on their inherent synergies. Cenix is providing research services for the life science industry and academic groups, focusing on the combination of high throughput (HT) RNAi with high content (HC) assays in human and rodent cells. For those groups capable of carrying out such large scale studies themselves, Definiens is providing its uniquely powerful image analysis software system, Cellenger®, based on Definiens' Cognition Network Technology.
As Cenix has constantly sought to further strengthen its capabilities in microscopy-based screening and automated image analysis, its scientists have tested a wide range of third party solutions from academia and industry efforts alike. Its early analysis of Cellenger® software in the context of genome-scale RNAi-based screens in human cells convinced Cenix to invest further efforts in assisting Definiens with the development and marketing of this world-class package.
Other news from the department business & finance
These products might interest you
Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management
ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration
